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ABSTRACT: Despite a long history of successful use, routine application of
some anticoagulant rodenticides (ARs) may be at a crossroad due to new
regulatory guidelines intended to mitigate risk. An adverse outcome pathway
for ARs was developed to identify information gaps and end points to
assess the effectiveness of regulations. This framework describes chemical
properties of ARs, established macromolecular interactions by inhibition of
vitamin K epoxide reductase, cellular responses including altered clotting
factor processing and coagulopathy, organ level effects such as hemorrhage,
organism responses with linkages to reduced fitness and mortality, and
potential consequences to predator populations. Risk assessments have
led to restrictions affecting use of some second-generation ARs (SGARs) in
North America. While the European regulatory community highlighted
significant or unacceptable risk of ARs to nontarget wildlife, use of SGARs in
most EU member states remains authorized due to public health concerns and the absence of safe alternatives. For purposes of
conservation and restoration of island habitats, SGARs remain a mainstay for eradication of invasive species. There are significant
data gaps related to exposure pathways, comparative species sensitivity, consequences of sublethal effects, potential hazards of
greater AR residues in genetically resistant prey, effects of low-level exposure to multiple rodenticides, and quantitative data on
the magnitude of nontarget wildlife mortality.
■ HISTORY AND USE OF ANTICOAGULANT
RODENTICIDES
Anticoagulant rodenticides (ARs) are used worldwide for
vertebrate pest control in urban and suburban settings,
agriculture, and island restoration projects. These compounds
block the vitamin K cycle and impede synthesis of active forms
of several blood clotting factors (II, VII, IX, and X) necessary
for hemostasis. Their discovery and development began with
Karl Paul Link’s investigations of “bleeding disease” in cattle
consuming improperly cured sweet clover.1 By 1940, Link
had isolated, crystallized and synthesized dicumarol (similar
in structure to vitamin K), that led to the synthesis of over
100 analogs with hemorrhagic properties, including the highly
potent compound number 42, warfarin. By the early 1950s,
warfarin was registered as a pesticide to control rats and mice,
and its clinical application as the “blood thinner” Coumadin
was approved for medicinal use, with U.S. President Dwight
Eisenhower being a prominent treatment recipient in 1955.
In the opening sentence of their review, Hadler and Buckle2
state, “Few modern pesticide groups have such a long history of
successful use as the anticoagulant rodenticides”, that continues
to this very day. These compounds revolutionized vertebrate
pest control. The first-generation anticoagulant rodenticides
(FGARs; e.g., warfarin, chlorophacinone, diphacinone) require
multiple feeds to cause death in rodents, but their use resulted
in the emergence of genetic resistance in rats and house mice.
The more potent and moderately persistent “superwarfarin”
second-generation anticoagulants rodenticides (SGARs; e.g.,
brodifacoum, difethialone, bromadiolone, difenacoum, flocoumafen)
were developed to overcome resistance and require only a single
bait feeding to cause death in target rodent species. Although
national and global AR market data are “confidential business
information”, estimates of AR use are illustrated by (i) a report
indicating production or import of 1764 kg of active ingredient
of four ARs in the U.S. in 1997,3 (ii) a market analysis suggest-
ing that U.S. homeowners spent $110 million on rodenticides in
2005,4 (iii) the sale of 454 t of formulated product in California
for agricultural purposes in 2007,5 (iv) use of approximately
544 t of bait containing AR by local authorities in the UK in
2001,6 and (v) application in over 700 of 1527 invasive species
eradication projects worldwide.7
Despite their evident success in agriculture and conservation-
based activities, continued use of some SGARs for control
of commensal rodents in urban, suburban, rural and even
agricultural settings may be at a crossroad. It is well-recognized
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that AR application is the only current method for rapid and
effective eradication of “established” rodent infestations.8,9 Large
scale applications of ARs have also been used to control
population peaks of small mammals (e.g., rodent plagues)
exhibiting demographic cycles.10 However, it is also apparent
that ARs are responsible for many unintentional exposures of
children (mostly minor and asymptomatic), companion animals
and nontarget wildlife, and a small fraction of such exposures
result in fatalities.11−15 New restrictions have been placed on the
use of some AR baits to mitigate risk.13,16 Herein, we present an
AR adverse outcome pathway (AOP), and briefly review risk
assessment data, recent regulatory changes on AR use in North
America and elsewhere, risk mitigation, conservation uses of
ARs, and unsolved issues on exposure and toxicity as they relate
to predatory birds and mammals.
■ ADVERSE OUTCOME PATHWAY FOR
ANTICOAGULANT RODENTICIDES
An AOP is a conceptual framework portraying existing
knowledge as a logical sequence of processes linking a direct
molecular initiating event to an adverse effect across multiple
levels of biological organization, which is relevant in risk assess-
ment.17−19 In an ecological context, population-level responses
are most germane for natural resource management, although
for species of special conservation status (e.g., threatened or
endangered, or highly valued to a particular stakeholder group),
effects at the level of the individual may have important popula-
tion consequences. The AOP framework has application in pre-
dictive and regulatory toxicology, particularly for well-studied
chemicals like ARs (Figure 1).
Chemical Properties and Macromolecular Interactions.
Anticoagulant rodenticides have low solubility in water and low
volatility.20 For all FGARs, and the SGARs bromadiolone and
flocoumafen, octanol:water partition coefficients (log Kow) are
less than 5, and thus have low or moderate bioaccumulation
potential. In contrast, the log Kow’s for the SGARs difethialone,
difenacoum and brodifacoum range from 5.17 to 8.50, and thus
these compounds exhibit greater potential for bioaccumulation.
Based upon studies examining the toxicity of 4-hydroxycoumarin
and indandione ARs to sensitive and resistant strains of rats,
bulky lipophilic extensions of the acetonyl side chain contribute
to their increased affinity to the active site of vitamin K epoxide
reductase, and compounds having tetrahydronaphthyl side-chains
(e.g., difenacoum) are more resistant to biotransformation.21
In contrast, FGARs are readily hydroxylated (notable excep-
tions include raptorial birds22) to inactive metabolites that are
excreted.23 Using solid-state structures of coumatetralyl and
chlorophacinone as input geometries, computational chemistry
efforts were conducted for 13 ARs.24 Structure−activity
relationship models suggest that toxicity is related to the length
and hydrophobicity of the side chain at carbon 13, with the most
active compounds having greater volume and bulky lipophilic
groups in this activity domain (Figure 2).21,24
Anticoagulant rodenticides bind tightly to and inactivate
vitamin K epoxide reductase (VKOR), an integral membrane
protein found on the rough endoplasmic reticulum in hepato-
cytes, and VKOR is also present in cells of other tissues.25
Catalytic activity of VKOR is necessary for the reduction of
both vitamin K epoxide and vitamin K to vitamin K hydro-
quinone, the biologically active form required for the γ-glutamyl
carboxylation of glutamine residues (Figure 3) on clotting
factors II (prothrombin), VII, IX, and X. The primary amino
acid sequence and the gene encoding VKOR have been well-
studied, and the membrane topology and active site (cysteine
sulfhydryl groups at residues 132 and 135 and warfarin binding
site at tyrosine 139) have been modeled (Figure 4).25
Inhibition of VKOR activity by warfarin, and other anticoagu-
lant rodenticides, limits the formation of vitamin K hydro-
quinone resulting in under-carboxylated clotting factors (e.g.,
des-γ-carboxy prothrombin)26 that will not assemble on cell
surfaces to form a clot (viz., molecular initiating/anchor event
in AOP, Figures 1 and 3). Vitamin K1 (phylloquinone) is an
Figure 1. Proposed Adverse Outcome Pathway for anticoagulant rodenticides in nontarget predatory wildlife.
Figure 2. Structure of the first-generation anticoagulant rodenticide
warfarin and the second- generation anticoagulant rodenticide
brodifacoum, illustrating side chains (red) of the activity domain
attached at carbon 13 (blue ∗).
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antidote to AR intoxication, and has long been used to
treat people, companion animals, and occasionally wildlife.27
Its administration results in the formation of the vitamin K
hydroquinone by DT-diaphorase, a vitamin K cycle enzyme
which is resistant to ARs,25 thus restoring carboxylation of
clotting factors.
Figure 3. Diagram of the vitamin K cycle showing two anticoagulant rodenticide (AR) sensitive vitamin K epoxide reductase (VKOR) reactions and
a warfarin-insensitive VKOR that reduces vitamin K to the biologically active vitamin K hydroquinone. Without adequate vitamin K hydroquinone,
γ-glutamyl carboxylase lacks substrate to adequately carboxylate clotting factors II, VII, IX, and X (adapted from Tie and Stafford 2008).25
Figure 4. Primary structure and membrane topology of the anticoagulant rodenticide-sensitive vitamin K epoxide reductase (adapted from Tie and
Stafford 2008).25 All single letter amino acid abbreviations follow IUPAC nomenclature. The warfarin binding site is Y139 (orange) and the active
redox sites are C132 and C135 (white). The most thoroughly studied mutation for warfarin resistance is at Y139; common mutations include
substitutions of S, C, and F, for Y. Other common mutations that afford warfarin resistance are indicated in yellow.9,30
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Widespread use of warfarin resulted in selection for warfarin-
resistant rats associated with reduced or reversible binding to
VKOR.21 Mutation of the VKOR gene coding tyrosine 139 and
amino acid substitutions at other locations can confer resistance
to FGARs28−30 and some SGARs.9 There is also evidence that
resistance can be conferred by other mechanisms including
increased AR clearance associated with enhanced CYP3A2
expression.31
Cellular Responses. Blood coagulation is the central
component of hemostasis.32 At the cellular level, coagulation
is initiated through an extrinsic pathway (tissue factor pathway)
with the generation of tissue factor that complexes with
carboxylated factor VII, which in turn activates factor X in
the common pathway, and to a lesser degree in the intrinsic
pathway (contact activation pathway), where factor IX is
activated. Factors XI and XII of the intrinsic pathway are absent
altogether in several avian species.33 Through the common
pathway, a number of reactions lead to the activation of
prothrombin to form thrombin. Thrombin cleaves circulating
fibrinogen into soluble fibrin monomers that polymerize, and it
also activates factor XIII, which in the presence of calcium cross-
links the polymer to form insoluble fibrin. In the classic cascade
model, thrombin formation is markedly amplified through the
intrinsic pathway. However, in vivo hemostasis is now better
described by a cell-based model, in which stages overlap and are
controlled by cellular components rather than protein levels and
kinetics,34 with alterations in factor IX having greatest effects on
thrombin generation and clotting.35
Measurement of clotting time (e.g., prothrombin time, partial
thromboplastin time, activated partial thromboplastin time)
of citrated plasma has long been used as a routine diagnostic
tool for AR intoxication in companion animals and people. Its
application to diagnose AR intoxication in captive and free-
ranging wildlife is rare.36 Clotting time assays are sensitive,
precise, inexpensive, linked to the pathogenesis of toxicity, and
have applicability as biomarkers of exposure and effect in both
controlled studies and field monitoring (Figure 1). In wildlife,
lengthening of prothrombin time by more than 25%37,38 or
two standard deviations above baseline values39 is suggestive
of anticoagulant exposure, and best confirmed by analytical
detection of AR residues in blood or tissue.
Following exposure to warfarin and other ARs, there is a lag
period of one to several days before coagulopathy (detectable
with biomarkers) becomes apparent. This is because fully
carboxylated functional clotting factors, with half-lives ranging
from 6 to 120 h40 support hemostasis, but once cleared clotting
is impaired (viz., key event in AOP, Figure 1). This lag period is
well-documented in people, companion animals, laboratory
rodents, and even raptorial birds.41−43 Upon termination of AR
exposure, coagulopathy can be resolved in a matter of days or
weeks,41,43 but VKOR activity may remain partially inhibited
for weeks to months, reducing reserve capacity to synthesize
vitamin K, and thus rendering animals highly sensitive to
subsequent AR exposures.44
Multiple Organ System Responses. Animals can exhibit
massive blood loss and succumb from fatal hemorrhage, but
lethality can also result from small microscopic bleeds resulting
in localized ischemia, hypoxia and cell death at vital sites (e.g.,
brain, heart, liver).12,39,42 Aside from AR effects on hemostasis,
there are many less well-established responses related to the
impairment of the vitamin K cycle (viz., plausible linkage in
AOP, Figure 1). For example, pediatric warfarin therapy can
reduce bone density and increase incidence of fractures due to
undercarboxylation of osteocalcin, the protein incorporating
calcium into bone,45 although in the single study conducted in
SGAR-exposed predatory birds, no such effect was found.46
Warfarin has been shown to exert anti-inflammatory effects,47
possibly by altering signal transduction,48 and also affect cell
proliferation by inhibiting vitamin K-dependent growth factors.49
In addition, the indandione rodenticides chlorophacinone and
diphacinone may also affect cellular energy generation by
uncoupling oxidative phosphorylation.50
Hemorrhage associated with coagulopathy can be spontaneous,
but is often initiated and certainly exacerbated by trauma, which
is not that unusual in free-ranging wildlife. A comprehensive
review11 provides 50 citations of affected sites and signs of
hemorrhage in various organ systems (e.g., integument,
musculoskeletal, respiratory, renal, gastrointestinal, reproductive,
central nervous system) associated with sublethal and fatal
AR poisoning in people. A similar tabulation of affected sites
and signs has yet to be compiled for nontarget wildlife,
although detailed results of necropsies do appear in some
reports.12,39,42,51,52 Overt signs often include bruising, bleeding
from the mouth, nares, rectum, cloaca, and talons, and blood in
droppings, scat and urine. Skin, mucus membranes, muscle and
viscera can appear pale due to blood loss. At necropsy, affected
sites often include skin, muscle, alimentary tract, peritoneal
cavity, kidney, and heart pericardium. Assessment of such effects
in animals found dead may be hampered due to deterioration of
organs and tissues, and hemorrhage due to freezing of carcasses
prior to necropsy.53 There can be excessive bleeding from
superficial wounds and hemorrhage from multiple sites. Blood
loss accompanying AR exposure is a function of dose and
frequency of exposure, and can range from mild to severe with
classification of an individual as being anemic, and is easily
quantified in vivo (e.g., reduced number of circulating red
blood cells, increased reticulocyte counts from stimulation of
hematopoiesis, and decreased hematocrit).12,27,39,41,54 Blood loss
can result in metabolic acidosis, tachycardia, and hypovolemic
shock,54 causing changes in tissue perfusion, organ dysfunction,
and tissue necrosis.
Whole Animal Responses. At the organismal level, inter-
individual variation seems to have a significant role in AR
toxicosis.12 Lethargy and abnormal posture are overt apical
responses frequently observed in toxicity studies, and often
described in AR-exposed wildlife undergoing rehabilitation.
Body condition and weight loss are mentioned in many reports,
and a significant negative relation between AR residues and
body condition has been found in stoats (Mustela ermine) and
weasels (Mustela nivalis).55 Furthermore, an association
between notoedric mange, mortality and AR exposure has
been described in bobcats (Lynx rufus) residing in urban areas
in southern California,56 although such relationships may be
correlative rather than causal. For example, animals suffering
from mange may be forced to forage in poor habitat in closer
proximity to people. Direct toxic effects of ARs on reproduction
in laboratory mammals, livestock and free-ranging raptorial
birds are somewhat equivocal,57−60 although the European
Chemicals Agency classifies some ARs as reproductive
toxicants.61 Clearly, such observations and data are difficult to
translate into measurable consequences affecting the fitness
(i.e., survival and reproduction) of free-ranging wildlife. Indirect
effects, such as altering availability of rodent prey species, could
certainly affect predator−prey dynamics.
Population Responses. Although rodenticides are widely
used, effects of ARs at the population level of predatory birds
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and mammals have not been established. Of the published
reports that examine exposure and unintentional wildlife
mortality,12,51,52,62−68 definitive diagnosis of poisoning (i.e.,
post-mortem signs of hemorrhage, independent of trauma,
coincident with the detection of rodenticide residues in liver)
generally accounts for but a small fraction of exposures (perhaps
<10%),12,60 with exceptions.51,67 As pointed out 15 years ago,
there is no evidence that rodenticide use causes large-scale
population declines of predatory and scavenging birds.69
However, AR exposure does have the potential to cause
additional mortality affecting populations “already experiencing
critical limitations”70 (viz., plausible linkage in AOP, Figure 1).
Furthermore, for long-lived predators or scavengers with low
reproductive rates (K-strategists), death of a few individuals
could theoretically affect local populations on a temporary basis.
In a contemporary effort to examine potential population
consequences of ARs, hepatic residues and associated signs of
intoxication were examined in a data set of 270 birds of prey
from Canada.71 Using an additive approach for SGAR residues
(bromadiolone + brodifacoum + difethialone; viz., toxic units)
and logistic regression plots to predict the probability of the
death of a bird with a liver residue of any given magnitude,
it was suggested that a minimum of 11% of the great horned
owl (Bubo virginianus) population in Canada is at risk of being
directly killed by SGARs. That assessment, however, was based
on exposure levels of great horned owls in areas with high
human population density and rodenticide use, and may not
apply across broad areas of the Canadian landscape. Regardless,
the prediction that 11% of the population of an abundant
K-strategic species is at risk from a single stress factor should be
carefully considered, and in some circumstances may not be
acceptable to natural resource managers.
There have been some instances of label-recommended
or permitted AR use that have resulted in mortality incidents
involving species of special conservation status or those
afforded special protection. For example, mortality incidents
have been reported for weka (Gallirallus australis; vulnerable-
IUCN Red List) in New Zealand,72 red kites (Milvus milvus;
near threatened-IUCN Red List) in Britain and France,73,74 and
bald eagles (Haliaeetus leucocephalus; Least Concern-IUCN Red
List but safeguarded by The Bald and Golden Eagle Protection
Act) in the U.S.75 There are less definitive incidents involving
the San Joaquin kit fox (Vulpes macrotis mutica; U.S. Federally
endangered species) and northern spotted owl (Strix
occidentalis caurina; near threatened-IUCN Red List).76 The
status of barn owl (Tyto alba) populations in southwestern
British Columbia, Canada was recently up-listed to threatened
due to many stressors including poisoning by rodenticides.65,77
In such circumstances, an organismal response (i.e., death of
an individual of a threatened or endangered species), rather
than a population-level response, may be considered an
anchoring event17 in an AOP. Nonetheless, incidental take of
a few individuals of a Federally listed species may be permitted
under current regulations, as is the case for the black-footed
ferret (Mustela nigripes), gray wolf (Canis lupus) and northern
aplomado falcon (Falco femoralis) with Rozol Prairie Dog Bait
(chlorophacinone) application.78
■ ANTICOAGULANT RODENTICIDE RISK
ASSESSMENT FOR PREDATORS
Registration and Regulation. The use of pesticides
requires detailed regulatory evaluations that ensure the compound
does not pose an unacceptable risk to people or the environment.
Such assessments take into account economic, social and
environmental costs and benefits, and general requirements
(e.g., new products, reregistrations, sale, distribution, use, etc.)
of the vertebrate pesticide registration process.79 Adverse
reactions of nontarget species to pesticide active ingredients
are predicted from toxic effects observed in surrogate species
exposed in the laboratory. In the U.S., Canada and Europe, the
required data have been generated on standard toxicological
end points in traditionally used test species (e.g., bobwhite
quail, Colinus virginianus and mallard, Anas platyrhynchos),
and occasionally other species (historically, mustelids). In
New Zealand, an array of introduced mammals has been
included in registration studies for purposes of examining
AR efficacy. These data, coupled with field observations, and
residue and fate information, are used by regulatory agencies,
industry, and other entities conducting ecological risk assess-
ments.79 Registered products undergo periodic review, which
can be triggered by new findings and unexpected observations
following their use.
In the U.S., the use profile (e.g., application site and
method, formulation, pest species) of FGARs includes urban,
suburban, and rural areas, and agricultural fields, with
initial product registrations for warfarin dating back to 1950,
followed by diphacinone in 1960, and chlorophacinone in
1971.80 Registration of SGARs in the U.S. occurred much later
(brodifacoum 1979, bromadiolone 1980, difethialone 1995),80
and the use profile was far more restrictive and did not include
agricultural fields (some SGARs are permitted for agricultural
use in Europe). Product registrations for both FGARs and
SGARs have been granted for conservation purposes, including
eradication of invasive species on islands.79,81
Long after the initial registration of several FGARs and
SGARs in the U.S., multiple nontarget wildlife mortality incident
reports,80 several peer-reviewed publications,52,62,63,72,82 and
public interest at the time of the Reregistration Eligibility
Decision83 were the impetus to undertake a comparative risk
analysis of rodenticides.80 Using a multiattribute rating
technique (e.g., dietary risk quotient for primary exposure,
percent mortality in secondary exposure, active ingredient
retention time in blood and liver), the SGARs brodifacoum and
difethialone were identified as posing the greatest potential risks
to predatory and scavenging birds and mammals that feed on
poisoned target and nontarget animals. Attempts to evaluate the
risk of brodifacoum using probabilistic methods (i.e., dietary
dose, uptake, and depuration models, probability of encounter-
ing contaminated prey) were hampered by data gaps and major
uncertainties.84 Deterministic evaluations led the U.S. EPA to
request registrants to voluntarily withdraw certain ARs from the
marketplace.76
In the U.S. EPA’s comparative risk analysis, the FGARs
seemed to be less hazardous to both target and nontarget
species.80 Some of this analysis relied on acute toxicity data.
However, an acute exposure scenario is neither appropriate
nor environmentally relevant (i.e., may underestimate environ-
mental risk) as FGARs require multiple days of exposure to
evoke toxicity.85 Additionally, more FGAR bait is needed to
achieve the same level of pest control as with SGARs, and thus
the number of toxic units in the environment at the time of
application is likely to be the same or greater. Furthermore, the
development of FGAR resistance in commensal rodents may
result in greater potential for exposure of and risk to predatory
species.
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Risk Mitigation Measures. In 2008, the U.S. EPA
instituted measures to mitigate some nontarget risks of
SGARs. These included new requirements on points of sale
and distribution, and package size, to impede purchase by
residential homeowners, and product labeling to permit use in
and around agricultural buildings, but not human residences.13
New bait station requirements were also instituted to minimize
exposure of children, pets, and nontarget wildlife. Additional
exposure modeling and quantitative risk assessments to evaluate
direct bait ingestion (primary exposure) and consumption of
prey containing AR residues (secondary exposure) were under-
taken.4 Based on toxicity and toxicokinetics, risk quotients for
direct bait consumption indicated that under some exposure
scenarios both SGARs (brodifacoum, difethialone) and FGARs
(warfarin, chlorophacinone) exceeded levels of concern for
nontarget birds and mammals. Consumption of SGAR-exposed
prey also exceeded levels of concern for predatory birds and
mammals. While consumption of FGAR-exposed prey posed
a hazard for nontarget mammals, levels of concern were rarely
exceeded for birds.4 In some use scenarios (e.g., Rozol for
control of prairie dogs, Cynomys ludovicianus), label require-
ments even state that applicators must make multiple follow-up
visits after application to remove dead or dying target species to
mitigate hazard to nontarget scavengers and predators.86 Such
practices to reduce potential AR exposure of predators may not
always be followed.86,87 At the Federal Insecticide, Fungicide,
and Rodenticide Act Scientific Advisory Panel hearing in
November 2011, some shortcomings of this screening-level risk
assessment were identified, including data quality and inter-
pretation, and overreliance on unrealistic worst-case scenarios.88
The U.S. EPA risk mitigation decision has resulted in actions
to cancel consumer uses of some noncompliant rodenticides
(some products containing warfarin, brodifacoum, and difethi-
alone that failed to meet US EPA safety measures) though
over 30 AR products remain available that meet protective
standards.89 Notably, the active ingredient of some replace-
ment compounds (e.g., acute vertebrate pesticides such as
bromethalin) lack diagnostic tests and antidotes. In the U.S.,
a few states conduct additional regulatory review of pesticides,
and the State of California will be restricting the use of SGARs
to certified pesticide applicators as of July 1, 2014.90 The U.S.
EPA and the Canadian Pesticide Management and Regulatory
Agency collaborate to harmonize pesticide regulations in North
America. Risk mitigation measures similar to those proposed
by the U.S. EPA are now in effect in Canada, with some minor
variances (e.g., bromadiolone can be applied by registered users
along fence lines within 30 m of buildings).16,91
In Europe, a recent review (European Chemicals Agency)
under the European Community Biocidal Products Directive
(98/8/EC)92 has highlighted significant or unacceptable risk
of primary and/or secondary poisoning of birds and nontarget
mammals from some SGARs used as biocides.55,64,67,93−95
However, under this Directive the compounds were still
authorized for use because they are deemed essential for human
hygiene and public health, and appropriate alternatives are
not at hand. In 2012, a new EU Biocidal Products Regulation
(528/2012)96 was adopted with similar criteria for author-
ization. Under this regulation, all SGAR use will be re-evaluated
by the end of 2017. Requirement for any mitigation measures
to reduce risk to nontarget exposure is at the discretion of
individual EU member states. For example, in the United
Kingdom, SGAR use has been widespread in both urban and
rural environments.6,97−99 Brodifacoum, flocoumafen and the
more recently licensed difethialone have until now been
restricted to indoor use because of their perceived risk of
causing primary and secondary poisoning in nontarget species;
other SGARs and FGARs have until now been licensed for
indoor and outdoor use. There is prevalence of SGAR
application in agricultural holdings68 with concomitant wide-
spread exposure in rural areas of a range of nontarget avian and
mammalian predators.68,70,99−101 A recent UK review related to
the primary and secondary risks posed by all SGARs concluded
that there was insufficient scientific evidence to distinguish
between any of the SGARs in terms of their risk to nontarget
species.102 As a result, it is proposed that UK authorizations
will change during 2014 or beyond, such that all SGARs may
be used outdoors and there will be a stewardship program
fostering practices to minimize exposure of nontarget species.
Other EU member states may adopt alternate mitigation
measures. For example, discussions on outdoor use of SGARs
in The Netherlands are ongoing and it is proposed that SGARs
may be used outdoors by certified personnel, in combination
with certified Integrated Pest Management.
In New Zealand, brodifacoum typically has been the SGAR
of choice for controlling rodents, all of which are invasive
non-native species. However, repeated use of brodifacoum on
the two main islands has been associated with substantial
contamination of wildlife and game species, and secondary
poisoning of nontarget species.103 As a result, there has been
use of low-residue alternatives (cholecalciferol) for control of
possums and rodents, registration of para-aminopropiophenone
for control of larger pest species (stoats and weasels), and
exploration of some toxicant combinations (e.g., FGARs +
cholecalciferol) for control of rodents.104,105
Special Considerations for Use in Conservation. Anti-
coagulant rodenticides have been used extensively for the control
and eradication of introduced and invasive species,7,106,107
particularly for island ecosystems. The use of these compounds
in such settings is logistically complex and expensive, with the
theoretical restoration benefit outweighing the risk of nontarget
species mortality.81 In contrast to standard use of ARs for
commensal or agricultural rodent control, special regulatory
attention is given to the application of these compounds for
conservation purposes to restore habitat for native species. As an
example of conservation use, a Special Local Needs pesticide
registration for aerial broadcast of 0.005% diphacinone bait was
undertaken in Hawaii to control rodents and wild pigs (Sus
scrofa) in native ecosystems. Hazard was evaluated using both
deterministic108 and probabilistic109 methods for the endemic
Hawaiian hawk (Buteo solitarius), short-eared owl (Asio
f lammeus sandwichensis), and honeycreeper (Melamprosops
phaeosoma). These evaluations found that the quantity of tissue
that would have to be consumed by a predator in acute and
subacute exposure scenarios was great (often exceeding the
weight of the bird); thus, the risk to evoke lethality or pro-
longed clotting time was low. As previously mentioned, an acute
exposure scenario is neither appropriate nor environmentally
relevant for assessing risks of FGARs.85 These assessments
using data from traditional wildlife test species may have
underestimated risk as recent studies have demonstrated that
raptors are far more sensitive to diphacinone than previously
thought.39,42,43 Application of American kestrel (Falco sparverius)
and Eastern screech-owl (Megascops asio) toxicity data for
diphacinone in previous deterministic assessments,4,108 and
in probabilistic assessments,39,110 suggest greater hazard to
predatory birds than previously realized. Nonetheless, FGARs
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are believed by some to be much less hazardous (perhaps by an
order of magnitude)72 than SGARs, presumably due to their
shorter half-life in tissues and multiday exposure required to
cause toxicity. These findings also demonstrate the importance of
dose−response relationships, including use of toxic reference
values,43,110 to link a biomarker (clotting time) or tissue residues
to an adverse effect. Such data are of value to natural resource
managers. However, it is difficult to extrapolate the internal dose
with effects across species and multiple studies. The AOP
construct provides the basis to fill in these data gaps that may be
used to help model and interpret dose−response relationships.17
■ UNSOLVED ISSUES
There are significant unknowns related to exposure and effects
to predatory wildlife associated with use of ARs. Among these
are basic and applied data needs to supplement risk assess-
ments. Some of these data are best derived from controlled
exposure trials using captive animals, while other information
can only be generated from field observations and hypothesis-
driven eco-epidemiological studies, and even a combination of
these activities.
Exposure Pathways. While there are many conceptual
models,108,109 there are limited empirical field data detailing AR
exposure pathways and compound transfer to predatory wildlife
per se. This shortcoming was noted in the regulatory review
of a probabilistic risk assessment for brodifacoum.84 Many
studies have focused on consumption of poisoned rodents.
The exposure pathway starts with AR bait placement and its
ingestion by target species. Secondary exposure of predatory
and scavenging wildlife occurs exclusively through their diet,
which at times can be quite variable. For example, a recent
investigation identified the primary target organism, Norway
rats (Rattus norvegicus), as the most important source of SGARs
for several species of owls at farms in British Columbia,
Canada.91 Small mammals, songbirds, and invertebrates were
also components of the exposure pathway for secondary
consumers in this study.91
Exposure pathways can be complex, with nontarget predators
encountering a combination of ARs. Notably, tissues analyzed
from mortality incidents document exposure to multiple
SGARs to varying degrees,12,51,52,56,62,63,65,68,71,100 and occa-
sionally even combinations of FGARs and SGARs.51,56 That
suggests some predators may reside and forage opportu-
nistically at the interface of urban/suburban/rural and
agricultural settings. For example, rats and nontarget small
mammals (but not house mice) exposed to SGARs while indoors
may move outdoors from unsealed buildings, and can travel con-
siderable distances before becoming available to predators.91,111
Likewise, the foraging range of many predators changes with
season. For example, commensal rats seem to be a significant
source of seasonal rodenticide exposure for polecats (Mustela
putorius) that favor farmyards during fall and winter months.100,112
Accordingly, estimating risk to nontarget predatory species by
extrapolation of toxicity data from single-compound controlled
laboratory and pen studies remains exceedingly difficult. As
demonstrated in highly inbred laboratory rats, combined SGAR-
FGAR exposures and their timing have marked effects on
toxicity,44 and deserve further attention from both an exposure
pathway and potential effect standpoint.
Many investigations have documented AR exposure of
invertebrates feeding on bait, and perhaps even small mammal
feces, rodent carcasses and soil-bound AR residues. Their
hazard to insectivorous birds and mammals has yielded mixed
findings as only a small fraction of the invertebrate food base
may be exposed in a treated area.91,113−116 However, some
suggest that ecological communities often contain both larger
numbers of individuals and more species of insectivorous
vertebrates compared to top-level vertebrate predators, and
thus AR-contaminated invertebrates might actually pose a
greater risk to this feeding guild than previously thought.117
A significant data gap remains for insectivorous vertebrates,
some of which may be ecologically vulnerable in island eradica-
tion projects.118,119
In contrast to the aforementioned terrestrial exposure
pathway, there is now evidence that warfarin, at nanogram per
liter quantities, is detectable in some wastewater effluents.120
Its source is presumed to be of human origin. However, based
on both its low concentration and log Kow (2.37), it is highly
unlikely that this is a significant source of exposure for predatory
wildlife.
Macromolecular to Population-Level Effects. Remark-
able differences in AR sensitivity have been reported in some
omnivorous and predatory birds compared to commonly tested
avian granivores.39,42,72,110 Although interspecific variation in
VKOR activity and AR metabolism may account for these
observations,22 there remains a need for additional comparative
toxicity and metabolism data for predatory species. Further-
more, the relative in vitro potency of various ARs to VKOR,121
and their use in additive toxicity models (e.g., toxic units or
equivalents) should be further examined as it could serve as an
alternative method reducing the need for some in vivo testing.
It might be possible to screen for AR sensitivity of predatory
wildlife by cross-species comparison of the primary structure of
VKOR to that found in resistant target species, as has been
done for the arylhydrocarbon and steroid hormone receptors,
and other ligand binding sites.122−124 However, such
predictions do not account for interspecific differences in AR
absorption, distribution, metabolism and elimination. While
the role of vitamin K deficiency in hemorrhagic syndrome in
chickens, and warfarin sensitivity and resistance in rats, has
been studied in great detail,125 vitamin K status has not been
evaluated in predatory wildlife, and could be a major factor in
AR susceptibility and tolerance.
Controlled AR exposure studies have principally focused on
overt signs of toxicity and mortality, occasionally included
measurement of AR residues and sublethal responses (e.g.,
behavior, condition, histopathology), and rarely quantification
of blood clotting.72,80,126 There are key issues and even
deficiencies in such studies, including the use of artificial test
conditions (e.g., no-choice continuous feed scenarios), and that
spontaneous hemorrhage in AR-exposed animals is a “multi-
causative phenomena” affected by stress and other variables.127
Many of these controlled studies failed to measure AR ingestion
rate and concentration of residues in tissue that are needed to
derive dietary- and tissue-based toxic reference values, and to
estimate internal dose for modeling toxicokinetics.
A longstanding issue related to ARs, and environmental
contaminants in general, is the significance of sublethal effects.
As illustrated in the AOP (Figure 1), several responses may
have hypothetical, plausible, or established linkages foreshadow-
ing higher order organismal or even population-level effects.
Based on existing data, predatory wildlife exposed to ARs
either survive, with seemingly little or no direct long-term
consequences, or they die. Alternatively, it is certainly possible
that the proximate cause of death of an individual seemingly
unrelated to poisoning might ultimately have been triggered by
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AR residues and coagulopathy. This may be responsible for the
absence of clear dose−response relationships. For example, a
detailed analysis of birds of prey admitted to a veterinary clinic
revealed that while 86% of 161 raptors contained AR residues,
only 6% could be diagnosed as having succumbed from AR
toxicosis.12 No significant relation between liver brodifacoum
residues and death was found, although the small number of
individuals that died from causes other than trauma may have
confounded this analysis.12 Nonetheless, some contend that AR
exposure is one of many chemical insults affecting “condition”
(e.g., lethargy could impair hunting, loss of body mass could
reduce energy stores during winter), susceptibility to disease,
resilience (e.g., recovery from nonfatal collisions, accidents and
trauma), tolerance to extreme weather, and even sensitivity to
other toxicants (e.g., Pb that can result in anemia), and could
exacerbate blood loss during molt. This impaired condition
hypothesis remains challenging to test and resolve.
There is some evidence that SGARs are one of several factors
(e.g., low food availability with the shift to intensive farming,
road mortality, loss of roost sites) that may be responsible for
declining populations of some species of predatory birds.65,77
Based on extensive personal observations over a 21-year period
(but not formal surveys), a decline in numbers of breeding pairs
of raptors, and some circumstantial evidence of secondary AR
poisoning, was noted with initiation of Klerat (active ingredient
brodifacoum) use on sugar cane in Queensland, Australia.57
Recent studies examined barn owl reproduction at oil palm
plantations in Malaysia that were baited with warfarin or
brodifacoum58 and bromadiolone or chlorophacinone.59 Over
several breeding cycles, both owl hatching and fledging success
in treated plots were significantly lower compared to the
reference area. It was suggested that impaired reproductive
performance was due to sublethal AR exposure of adults and
nestlings, although confounding effects of reduced rat popula-
tions on reproductive parameters could not be discounted.
Clearly, the direct and indirect consequences and uncertainties
of ARs on reproduction and population responses in predatory
species deserve further attention.
Exposure and Mortality Incidents. Some suggest that AR
risk to predatory birds and mammals has been overestimated,
with the proportion of mortality being quite low in comparison
to actual use.3,69 Anecdotal reports favor solitary events (e.g.,
death of a snowy owl, Nyctea scandiaca, which established
residence near a correctional facility using 0.2% diphacinone
tracking powder, with stomach contents full of rat remains).52
Likewise, in agricultural settings, the risk to nontarget wildlife is
generally perceived to be minimal3,127 as the vast majority of
applications involve FGARs on croplands and fields for grazing
livestock. However, baits with the SGAR bromadiolone or
the FGAR chlorophacinone have been responsible for some
mortality of predatory and scavenging wildlife in France.51,74,94
For eradication efforts involving introduced species on remote
islands, practical experience has demonstrated that some
projects create a surplus of readily available dead and dying
rodents that can cause significant mortality of predatory birds
(e.g., mortality of bald eagles and ravens with brodifacoum use
on Langara Island, British Columbia;106 carcasses and remains
of 46 bald eagles associated with brodifacoum application on
Rat Island, Alaska75). These findings demonstrate that patterns
of AR use for control of commensal rodents and introduced
species can result in a range of consequences.
Perhaps the greatest unknowns are quantitative estimates of
the magnitude of nontarget predator mortality associated with
AR use. Few rigorously designed field trials have focused
on FGAR or SGAR exposure and effects on predators,3,128
although two radiotelemetry studies generated some survival
data which identified brodifacoum as a significant hazard
to raptors in orchards.129,130 In a more recent study, risk
predictions suggested that bromadiolone application for control
of the water vole (Aricola terrestris) posed a significant hazard to
red kites.94 While field surveys of the treated area detected
three dead kites, and one moribund individual with clinical
signs suggestive of AR exposure, residue concentrations did not
confirm bromadiolone poisoning. Use of banding and radio-
telemetry techniques with insectivorous and predatory birds
during efforts to eradicate introduced species in New Zealand
have documented mortality associated with some formulations
of brodifacoum (e.g., insectivorous weka on Ulva Island;72
morepork, Ninox novaseelandiae on Mokoia Island131). The vast
majority of efforts to monitor AR effects on predators during
field applications and eradication projects have entailed direct
count observations, call counts, and carcass searches, all of
which have varying degrees of inherent bias. While exposure of
nontarget wildlife to ARs used for commensal rodent control is
well-documented in urban and suburban settings,12,56 overall
effects on population dynamics have not been addressed. More
rigorous efforts in monitoring of nontarget mortality should
be routinely incorporated into pest control and eradication
projects, assessing both short-term and long-term impacts to
predatory species.
More extensive monitoring efforts on the magnitude of
nontarget predator mortality could add to our ability to gauge
the overall effects of new risk mitigation measures. Wildlife
exposure and mortality incident schemes (e.g., Ecological
Incident Information System of the U.S. EPA, the Predatory
Bird Monitoring Scheme and the Wildlife Incident Inves-
tigation Scheme of the UK, and Wildlife Disease Surveillance
System in France) have been the primary source of wildlife
exposure data to date. However, the relationship among AR
residues and their relative potencies, sublethal effects, and
mortality are poorly defined and difficult to extrapolate between
species.12,60 Hepatic AR residues bound to high affinity and low
affinity sites are not always a proxy of recent exposure or
effect,132,133 and in some instances pathological evaluations are
incomplete, and potentially compromised by disease and post-
mortem storage conditions.53
Resistance. Genetic-based resistance to FGARs and SGARs
in commensal rodents has been documented in numerous
locations,8,9,29,30 and it has been suggested to be a factor that
could theoretically impact exposure of predatory wildlife.60
There is no formally published evidence that resistant rodents
accumulate greater body burdens of ARs compared to sensitive
individuals.31,134,135 However, compared to dead and often
concealed rats,73 the survival of AR-exposed resistant
individuals for extended periods might enhance the likelihood
of secondary poisoning of predators.60,134,135 The role of
resistance in mediating exposure, risk and even adaptation of
nontarget species has not been adequately evaluated.
■ ALTERNATIVES
While not the intent of this review, it is worth noting that in
addition to AR registration and label restrictions, there are
multiple activities that attempt to minimize or prevent exposure
and adverse effects to nontarget wildlife. Some large commercial
users of rodenticides (e.g., Wal-Mart) have shown leadership in
implementing such measures.136 For large-scale applications and
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eradication projects, these include carcass removal accompanied
by appropriate disposal, raptor capture and hold/relocation,
hazing, and in some situations seasonal timing of baiting to
reduce exposure of migratory species. For smaller scale activities,
education and outreach programs foster appropriate AR use
(e.g., integrated pest management that includes habitat alteration,
sanitation, exclusion of commensal pest species) and other
practices (e.g., concealing bait to minimize nontarget exposure,
carcass disposal, removing bait at end of treatment).137,138 On a
global scale, the number of registered vertebrate pesticides has
actually “plummeted” over the last 50 years, with few newly
registered compounds.82 There are some acute vertebrate pesticides
(e.g., bromethalin, cholecalciferol, zinc phosphide) for which
secondary poisoning potential of nontarget wildlife is low, but
these compounds show high acute toxicity, lack specific antidotes
and may not be suitable for use in close proximity to man, while
other compounds (e.g., sodium fluoroacetate, strychnine) lack
effective antidotes and are considered inhumane. Recent research
and development efforts have resulted in registration of para-
aminopropiophenone in 2011105 for control of larger pest species
(stoats and weasels) in New Zealand. In addition, the combination
of an FGAR and acute vertebrate pesticide (e.g., coumatetralyl +
cholecalciferol) was at one time used in Germany139 and is now
undergoing trials for potential registration in New Zealand.105
Other innovations include new delivery systems and bait
coatings,105 although their effectiveness has not been completely
evaluated in the field. Biological controls, such as attracting raptors
to predate rodents,140,141 interaction of pathogens to reduce AR
doses in baits,142 and use of the highly pathogenic protozoan
Sarcocystis singaporensis to debilitate rodents,143 have been
advocated by some, but do not result in rodent elimination.
■ CONCLUSIONS
Anticoagulant rodenticides are one of the principal vertebrate
pesticides for the control of commensal rodents that damage
crops and food stores, and cause health issues, as well as for the
eradication of invasive species to restore biodiversity to oceanic
islands. By constructing an AOP for ARs as they relate to
nontarget predatory species, it is apparent that the “mechanism
of action” from the molecular through cellular levels of
organization is well-understood. However, our knowledge of
the linkages and forecasting of responses at the level of the
individual (behavioral, physiological, survival) through popula-
tion (recruitment) is incomplete for this well-studied class of
vertebrate pesticide agents. Effects of ARs on predatory birds
and mammals at the population level have not been conclusively
established. Our knowledge of the hazard associated with
resistance development, that could potentially increase AR
concentrations in target species, is inadequate. At these higher
levels of biological organization, our understanding is less
complete and characterized as “mode of action”,17 which is the
case for many classes of pesticides and environmental
contaminants. While we have identified numerous information
needs, perhaps the most critical uncertainties related to AR risks
to nontarget wildlife include (i) more complete understanding of
exposure pathways, (ii) comparative sensitivity among predatory
species, (iii) the relation among residues of multiple ARs, their
relative potency, and combined effect at the level of the
individual, (iv) quantitative estimates of mortality, particularly in
light of new regulations that attempt to mitigate adverse effects,
(v) identification of the occurrence of sublethal effects and their
higher-tier population and long-term ecological consequences,
and (vi) the effects of multiple low-level AR exposures.
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(67) Sańchez-Barbudo, I. S.; Camarero, P. R.; Mateo, R. Primary and
secondary poisoning by anticoagulant rodenticides of non-target
animals in Spain. Sci. Total Environ. 2012, 420, 280−288.
(68) Hughes, J.; Sharp, E.; Taylor, M. J.; Melton, L.; Hartley, G.
Monitoring agricultural rodenticide use and secondary exposure of
raptors in Scotland. Ecotoxicology 2013, 22, 974−984.
(69) Smith, R. H. Population biology and non-target effects of
rodenticides: Trying to put the eco into ecotoxicology. In Advances in
Vertebrate Pest Management; Cowan, D. P., Feare, C. J., Eds.; Filander
Verlag: Furth, Germany, 1999; pp 331−346.
(70) Brakes, C. R.; Smith, R. H. Exposure of non-target small
mammals to rodenticides: Short-term effects, recovery and implica-
tions for secondary poisoning. J. Appl. Ecol. 2005, 42, 118−128.
(71) Thomas, P. J.; Mineau, P.; Shore, R. F.; Champoux, L.; Martin,
P. A.; Wilson, L. K.; Fitzgerald, G.; Elliott, J. E. Second generation
anticoagulant rodenticides in predatory birds: Probabilistic character-
isation of toxic liver concentrations and implications for predatory bird
populations in Canada. Environ. Int. 2011, 37, 914−920. and
corrigendum, 40, 256.
(72) Eason, C. T.; Murphy, E. C.; Wright, G. R. G.; Spurr, E. B.
Assessment of risks of brodifacoum to non-target birds and mammals
in New Zealand. Ecotoxicology. 2002, 11, 35−48.
(73) Burn, A. J.; Carter, I.; Shore, R. F. The threats to birds of prey in
the UK from second-generation rodenticides. Aspects. Appl. Biol. 2002,
67, 203−212.
(74) Berny, P.; Gaillet, J.-R. Acute poisoning of red kites (Milvus
milvus) in France: Data from the SAGIR network. J. Wildl. Dis. 2008,
44, 417−426.
(75) The Rat Island Rat Eradication Project: A Critical Evaluation of
Nontarget Mortality; The Ornithological Council: Bethesda, MD, 2010;
http://www.seabirdrestoration.org/pdf/RatIslandReview.pdf.
(76) Risk Mitigation Decision for Ten Rodenticides, EPA-HQ-OPP-
2006-0955-0764; Unites States Environmental Protection Agency:
Washington, DC, 2008; http://www.epa.gov/oalj/filings/Reckitt_
HrgReq_Ex03.pdf.
(77) Huang, A. C.; Elliott, J. E.; Martin, K.; Hindmarch, S. SARA-
listed (Species At Risk Act) barn owls (Tyto alba) in British Columbia:
Genetic diversity, connectivity, and divergence. In Raptor Research
Foundation Annual Meeting, Bariloche, Argentina, 2013; http://www.
raptorresearchfoundation.org/wp-content/uploads/2013/10/
WorldwideRaptorConferenceProgram.pdf.
(78) Final Biological Opinion for Rozol® Use on Black-Tailed Prairie
Dogs Registered under Section 3 of the Federal Insecticide, Fungicide and
Rodenticide Act; U.S. Fish and Wildlife Service: Denver, CO, 2012;
http://www.epa.gov/espp/2012/borozol-final.pdf.
(79) Eason, C. T.; Fagerstone, K. A.; Eisemann, J. D.; Humphrys, S.;
O’Hare, J. R.; Lapidge, S. J. A review of existing and potential New
World and Australasian vertebrate pesticides with a rationale for
linking use patterns to registration requirements. Int. J. Pest Manag.
2010, 56, 109−125.
(80) Erickson, W.; Urban, D. Potential Risks of Nine Rodenticides to
Birds and Nontarget Mammals: A Comparative Approach; Office of
Prevention, Pesticides and Toxic Substances, U.S. Environmental
Protection Agency: Washington, DC, 2004; http://www.fluoridealert.
org/wp-content/pesticides/EPA-HQ-OPP-2006-0955-0005.pdf.
(81) Witmer, G.; Eisemann, J. D.; Howald, G. The use of
rodenticides for conservation efforts. Wildl. Damage Manage. Conf.
2007, 12, 160−167.
(82) Eason, C. T.; Spurr, E. B. Review of the toxicity and impacts of
brodifacoum to non-target wildlife in New Zealand. N. Z. J. Zool. 1995,
22, 371−379.
(83) Reregistration Eligibility Decision (RED) Rodenticide Cluster, EPA
738-R-007, Prevention, Pesticides and Toxic Substances; U.S. Environ-
mental Protection Agency: Washington, DC, 1998; http://www.epa.
gov/oppsrrd1/REDs/2100red.pdf.
(84) OPP Evaluation of Cadmus/Brodifacoum Registrants (C/BR)
Probabilistic Risk Assessment Model of Brodifacoum, EPA-HQ-OPP-
2011-0718-0085; Environmental Fate & Effects Division, U.S.
Environmental Protection Agency: Washington, DC, 2005; http://
www.regulations.gov/#!documentDetail;D=EPA-HQ-OPP-2011-
0718-0085.
(85) Vyas, N. B.; Rattner, B. A. Critique on the use of the
standardized avian acute oral toxicity test for first generation
anticoagulant rodenticides. Human Ecol. Risk Assess. 2012, 18, 1069−
1077.
(86) Vyas, N. B. Untested pesticide mitigation requirements:
Ecological, agricultural, and legal implications. Drake J. Agri. Law.
2013, 18, 335−348.
(87) Tosh, D. G.; Shore, R. F.; Jess, S.; Withers, A.; Bearhop, S.;
Montgomery, W. I.; McDonald, R. A. User behaviour, best practice
and the risk of non-target exposure associated with anticoagulant
rodenticide use. J. Environ. Manage. 2011, 92, 1503−1508.
(88) A Set of Scientific Issues Being Considered by the Environmental
Protection Agency Regarding: Scientific Conclusions Supporting EPA’s
Environmental Science & Technology Critical Review
dx.doi.org/10.1021/es501740n | Environ. Sci. Technol. 2014, 48, 8433−84458443
FIFRA Section 6(b) Notice of Intent to Cancel Twenty Homeowner
Rodenticide Bait Products; Office of Chemical Safety and Pollution
Prevention, U.S. Environmental Protection Agency: Washington, DC,
2011; ht tp://www.epa .gov/sc ipoly/sap/meet ings/2011/
112911finalsap_mtg_mins.pdf.
(89) Rodent Products for Consumers; U.S. Environmental Protection
Agency: Washington, DC, 2014; http://www.epa.gov/pesticides/
mice-and-rats/consumer-prod.html#risk.
(90) Designating Brodifacoum, Bromadiolone, Defenacoum, And
Difethialone (Second Generation Anticoagulant Rodenticides) As
Restricted Materials. Final Text of Regulation, DPR 13-002; Department
of Pesticide Regulation, California Environmental Protection Agency:
Sacramento, CA, 2014; http://www.cdpr.ca.gov/docs/legbills/
rulepkgs/13-002/13-002.htm.
(91) Elliott, J. E.; Hindmarch, S.; Albert, C. A.; Emery, J.; Mineau, P.;
Maisonneuve, F. Exposure pathways of anticoagulant rodenticides to
nontarget wildlife. Environ. Monit. Assess. 2014, 186, 895−906.
(92) Elsmore, R. Biocidal product authorisations under the BPD
(98/8/EC). Chim. Oggi-Chem. Today 2010, 28, 34−36.
(93) Christensen, T. K.; Lassen, P.; Elmeros, M. High exposure rates
of anticoagulant rodenticides in predatory bird species in intensively
managed landscapes in Denmark. Arch. Environ. Contam. Toxicol.
2012, 63, 437−444.
(94) Coeurdassier, M.; Poirson, C.; Paul, J.-P.; Rieffel, D.; Michelat,
D.; Reymond, D.; Legay, P.; Giraudoux, P.; Scheifler, R. The diet of
migrant red kites Milvus milvus during a water vole Arvicola terrestris
outbreak in eastern France and the associated risk of secondary
poisoning by the rodenticide bromadiolone. Ibis 2012, 154, 136−146.
(95) Langford, K. H.; Reid, M.; Thomas, K. V. The occurrence of
second generation anticoagulant rodenticides in non-target raptor
species in Norway. Sci. Total Environ. 2013, 450−451, 205−208.
(96) Regulation (EU) No 528/2012 of the European Parliament and
of the Council of 22 May 2012 concerning the making available on the
market and use of biocidal products. Official Journal of the European
Union L167 Vol. 55 27 June 2012; http://eur-lex.europa.eu/
LexUriServ/LexUriServ.do?uri=OJ:L:2012:167:FULL:EN:PDF.
(97) McDonald, R. A.; Harris, S. The use of fumigants and
anticoagulant rodenticides on game estates in Great Britain. Mammal
Rev. 2000, 30, 57−64.
(98) Dawson, A.; Bankes, J.; Garthwaite, D. G. Pesticide Usage Survey
Report 175: Rodenticide Usage on Farms in Great Britain Growing Arable
Crops 2000, PB 8016; Department of the Environment, Food & Rural
Aff a i r s : UK , 2 0 0 3 ; h t t p : / /www . f e r a . d e f r a . g o v . u k /
landUseSustainability/surveys/9099surveys.cfm.
(99) Tosh, D. G.; McDonald, R. A.; Bearhop, S.; Lllewellyn, N. R.;
Fee, S.; Sharp, E. A.; Barnett, E. A.; Shore, R. F. Does small mammal
prey guild affect the exposure of predators to anticoagulant
rodenticides? Environ. Pollut. 2011, 159, 3106−3112.
(100) Shore, R. F.; Birks, J. D. S.; Afsar, A.; Wienburg, C. L.
Kitchener, A.C. Spatial and temporal analysis of second-generation
anticoagulant rodenticide residues in polecats (Mustela putorius) from
throughout their range in Britain, 1992−1999. Environ. Pollut. 2003,
122, 183−193.
(101) Walker, L. A.; Chaplow, J. S.; Llewellyn, N. R.; Pereira, M. G.;
Potter, E. D.; Sainsbury, A. W.; Shore, R. F. Anticoagulant Rodenticides
in Predatory Birds 2011: A Predatory Bird Monitoring Scheme (PBMS)




(102) Rodenticides and Biocides Legislation; Health and Safety
Executive. UK, 2014 http://www.hse.gov.uk/biocides/eu-bpr/
rodenticides.htm.
(103) Eason, C. T.; Henderson, R.; Hix, S.; MacMorran, D.; Miller,
A.; Murphy, E.; Ross, J.; Ogilvie, S. Alternatives to brodifacoum and
1080 for possum and rodent control-how and why? N. Z. J. Zool. 2010,
37, 175−183.
(104) Eason, C. T.; Ogilvie, S. A Re-Evaluation of Potential
Rodenticides for Aerial Control of Rodents; Department of Conservation,
Research and Development Series 312: Wellington, New Zealand,
2009; http://www.doc.govt.nz/documents/science-and-technical/
drds312entire.pdf.
(105) Blackie, H. M.; MacKay, J. W. B.; Allen, W. J.; Smith, D. H. V.;
Barrett, B.; Whyte, B. I.; Murphy, E. C.; Ross, J.; Shapiro, L.; Ogilvie,
S.; Sam, S.; MacMorran, D.; Inder, S.; Eason, C. T. Innovation
developments for long-term mammalian pest control. Pest Manage. Sci.
2014, 70, 345−351.
(106) Howald, G.; Donlan, C. J.; Galvań, J. P.; Russell, J. C.; Parkes,
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